Search Result

Results for "

Ige Inhibitors

" in MedChemExpress (MCE) Product Catalog:

標的別:	Acyltransferase (2) Adrenergic Receptor (1) Antibiotic (2) Apoptosis (3) Bacterial (2) Bcl-2 Family (1) Btk (1) Calcium Channel (1) Caspase (1) Cathepsin (1) Cholinesterase (ChE) (2) COX (2) CXCR (6) Drug Derivative (1) Drug Intermediate (1) Endogenous Metabolite (1) ERK (2) Fc Receptor (FcR) (4) Fungal (2) G Protein-coupled Receptor Kinase (GRK) (1) Glutathione S-transferase (1) Glycosidase (1) Heme Oxygenase (HO) (1) Histamine Receptor (13) Interleukin Related (9) Isotope-Labeled Compounds (3) Itk (1) JNK (2) Mas-related G-protein-coupled Receptor (MRGPR) (3) MMP (1) Neuropeptide Y Receptor (1) NF-κB (2) NO Synthase (3) Opioid Receptor (1) p38 MAPK (2) Parasite (1) PARP (2) Phosphodiesterase (PDE) (3) PPAR (1) Prostaglandin Receptor (2) Reactive Oxygen Species (ROS) (2) Reference Standards (3) ROCK (1) STAT (2) Syk (2) Target Protein Ligand-Linker Conjugates (1) TNF Receptor (5) Transmembrane Glycoprotein (1)
研究分野別:	Cancer (7) Cardiovascular Disease (4) Endocrinology (4) Infection (4) Inflammation/Immunology (47) Metabolic Disease (2) Neurological Disease (4)

標的別:

Acyltransferase (2)

Adrenergic Receptor (1)

Antibiotic (2)

Apoptosis (3)

Bacterial (2)

Bcl-2 Family (1)

Btk (1)

Calcium Channel (1)

Caspase (1)

Cathepsin (1)

Cholinesterase (ChE) (2)

COX (2)

CXCR (6)

Drug Derivative (1)

Drug Intermediate (1)

Endogenous Metabolite (1)

ERK (2)

Fc Receptor (FcR) (4)

Fungal (2)

G Protein-coupled Receptor Kinase (GRK) (1)

Glutathione S-transferase (1)

Glycosidase (1)

Heme Oxygenase (HO) (1)

Histamine Receptor (13)

Interleukin Related (9)

Isotope-Labeled Compounds (3)

Itk (1)

JNK (2)

Mas-related G-protein-coupled Receptor (MRGPR) (3)

MMP (1)

Neuropeptide Y Receptor (1)

NF-κB (2)

NO Synthase (3)

Opioid Receptor (1)

p38 MAPK (2)

Parasite (1)

PARP (2)

Phosphodiesterase (PDE) (3)

PPAR (1)

Prostaglandin Receptor (2)

Reactive Oxygen Species (ROS) (2)

Reference Standards (3)

ROCK (1)

STAT (2)

Syk (2)

Target Protein Ligand-Linker Conjugates (1)

TNF Receptor (5)

Transmembrane Glycoprotein (1)

研究分野別:

Cancer (7)

Cardiovascular Disease (4)

Endocrinology (4)

Infection (4)

Inflammation/Immunology (47)

Metabolic Disease (2)

Neurological Disease (4)

阻害剤およびアゴニスト

ペプチド

阻害性抗体

天然物

同位体標識化合物

Targets Recommended: Serpin

製品番号	製品名	Target	研究分野	構造式

HY-A0059

Nifuratel 3 Publications Verification NF 113; SAP 113; Methylmercadone	Bacterial Parasite Antibiotic Fungal Apoptosis STAT Interleukin Related TNF Receptor	Infection Inflammation/Immunology Cancer
Nifuratel (NF 113) is an orally active broad-spectrum antibiotic with antiprotozoal, antibacterial, anticancer and anti-inflammatory activities, and has good inhibitory effects on Candida and Trichomonas. Nifuratel is also a STAT3 inhibitor, which significantly inhibits the growth and proliferation of human gastric cancer cells and induces apoptosis. In addition, Nifuratel also inhibits mast cell-mediated antigen hypersensitivity reactions and can be used in the study of IgE-mediated allergic diseases .

HY-P990774

Verekitug ASP-7266; TRAB-1; UPB-101	Interleukin Related	Inflammation/Immunology
Verekitug (ASP-7266; TRAB-1; UPB-101) is a human monoclonal antibody targeting the thymic stromal lymphopoietin receptor (TSLPR), with a mean half-life of approximately 20 days. At doses of Verekitug ≥100 mg, complete and sustained TSLPR-specific occupancy is achieved, and the antibody does not bind to IL-7Rα. By inhibiting TSLP-driven inflammatory responses, Verekitug blocks TSLP-induced cell proliferation and TARC expression, while reducing fractional exhaled NO levels, blood eosinophil counts, and levels of IL-5 and *IgE*. Verekitug significantly improves scores for nasal polyps, nasal congestion and olfactory dysfunction, with favorable safety and good tolerability; potential adverse reactions include headache, upper respiratory tract infection, sinusitis and nasopharyngitis. Verekitug is used in relevant studies on asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease .

HY-P99300

Ligelizumab 1 Publications Verification QGE 031; Anti-IGHE Recombinant Antibody	Fc Receptor (FcR)	Inflammation/Immunology
Ligelizumab (QGE 031) is a humanized high-affinity anti-immunoglobulin *IgE* monoclonal antibody. Ligelizumab selectively inhibits the binding of IgE to the high-affinity receptor FcεRI, while the inhibitory effect on the low-affinity receptor CD23 is weak. Ligelizumab can inhibit the activation of effector cells such as mast cells and Basophil, while reducing the production of IgE by B cells, and restoring the IFN-α production and regulatory T cell (Treg) induction function of plasmacytoid dendritic cells (pDC). Ligelizumab can be used in the study of allergic diseases (such as chronic spontaneous urticaria, allergic asthma) .

HY-N0631

Cornuside 5+ Cited Publications	p38 MAPK NF-κB JNK Cholinesterase (ChE) Acyltransferase NO Synthase Interleukin Related TNF Receptor Prostaglandin Receptor ERK COX	Neurological Disease Inflammation/Immunology
Cornuside is an iridoid glycoside with anti-allergic, anti-inflammatory, and neuroprotective activities. Cornuside exerts anti-allergic activity by downregulating the p38 MAPK, JNK, and NF-κB signaling pathways, and inhibits IgE-mediated histamine release from mast cells. Cornuside improves cognitive impairment in mice by inhibiting BACE1 activity (IC₅₀ = 55.84 μg/mL) and enhancing ChAT activity. Cornuside inhibits LPS (HY-D1056)-induced inflammatory mediators, including iNOS, COX-2, PGE2, TNF-α, IL-6, and IL-1β, by suppressing NF-κB activation .

HY-P99371

Lirentelimab AK002; Antolimab	Apoptosis	Inflammation/Immunology
Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis .

HY-P991636

AK006	Transmembrane Glycoprotein	Inflammation/Immunology
AK006 is a humanized IgG1 monoclonal antibody agonist targeting Sialic acid-binding immunoglobulin-like lectin6 (Siglec-6). AK006 potently inhibits IgE-mediated human mast cell activation. AK006 can be used for inflammatory diseases like chronic urticaria (CU) and asthma research .

HY-114495

Caerulomycin A 3 Publications Verification Cerulomycin; Caerulomycin	Fungal Antibiotic	Infection Inflammation/Immunology
Caerulomycin A is an orally active immunomodulator and antimicrobial agent. Caerulomycin A targets Smad3, STAT1 and GATA-3. Caerulomycin A downregulates GATA-3 expression, inhibits Th2 cell differentiation and Th2 cytokine production, reduces IgE levels, and alleviates pulmonary inflammatory responses and eosinophil infiltration. Caerulomycin A ameliorates collagen-induced arthritis symptoms, reduces joint inflammation and synovitis, and decreases the levels of proinflammatory cytokines in joints. Caerulomycin A inhibits the growth of some filamentous fungi, yeasts and specific bacteria. Caerulomycin A can be used in research related to arthritis and asthma .

HY-16420

R112	Syk	Inflammation/Immunology
R112 is a fast and reversible inhibitor of spleen tyrosine kinase (Syk) kinase. R112 inhibits Syk kinase activity with an IC₅₀ value of 226 nM and a Ki value of 96 nM. R112 inhibits IgE-FcεRI signaling pathway. R112 can be used for the research of allergic rhinitis .

HY-17002

Suplatast (Tosilate) 1 Publications Verification IPD 1151T	Interleukin Related	Inflammation/Immunology
Suplatast Tosilate (IPD 1151T) is an orally active Th2 cytokine inhibitor which can inhibit both IL-4 and IL-5 production from Th2 cells and suppress IgE synthesis. Suplatast Tosilate is an anti-allergic agent. Suplatast Tosilate has antiasthmatic, anti-inflammatory and antifibrotic activity .

HY-43521

Ibrutinib-MPEA	Target Protein Ligand-Linker Conjugates Btk STAT	Inflammation/Immunology Cancer
Ibrutinib-MPEA is an orally active, blood-brain barrier permeable inhibitor of BTK and STAT5. As a derivative of Ibrutinib (HY-10997) conjugated with a PROTAC linker, Ibrutinib-MPEA allows the synthesis of a series of PROTAC molecules. Ibrutinib-MPEA significantly reduces the proliferation of neoplastic mast cells and primary mastocytoma cells by inducing apoptosis and inhibiting *IgE*-dependent histamine release. Ibrutinib-MPEA is applicable to the research of canine mast cell tumors, cerebral ischemia/reperfusion injury in diabetic mice, and neuroinflammation-related diseases .

HY-B0426A

Olopatadine hydrochloride ALO4943A; KW4679	Histamine Receptor CXCR	Infection Neurological Disease Metabolic Disease Inflammation/Immunology
Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific *IgE, while increasing the expression of ErbB3A/HER3A*. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .

HY-B0010B

Formoterol-1 1 Publications Verification (±)Formoterol	Adrenergic Receptor	Inflammation/Immunology
Formoterol ((±)Formoterol) is an orally active β2-selective agonist. Formoterol potently relaxes the peripheral airways through stimulating the beta 2-adrenoceptors selectively as is the case in the central airways and that it significantly inhibits IgE-mediated slow reactive substance of anaphylaxis (SRS-A) release through beta-adrenoceptor stimulation .

HY-139690

CCG258747 1 Publications Verification	Opioid Receptor G Protein-coupled Receptor Kinase (GRK) Mas-related G-protein-coupled Receptor (MRGPR)	Cardiovascular Disease Inflammation/Immunology
CCG258747 is a selective GRK2 inhibitor (IC₅₀ = 18 nM) with high selectivity over GRK1, GRK5, PKA, and ROCK1 (518, 83, > 5500, and > 550-fold, respectively). CCG258747 also blocks the internalization of the µ-opioid receptor (MOR). CCG258747 attenuates IgE mediated anaphylaxis by inhibiting GRK2 and FcεRI signaling pathway but activates mast cells via MRGPRX2 and MRGPRB2. CCG258747 can be used to study diseases related to overexpression of GRK2 (such as heart failure, opioid tolerance) .

HY-W062109

Olopatadine	Histamine Receptor CXCR	Inflammation/Immunology
Olopatadine (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific *IgE, while increasing the expression of ErbB3A/HER3A*. Olopatadine can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .

HY-P1130

M871 Galanin-(2-13)-Glu-His-(Pro)3-(Ala-Leu)2-Ala-amide	Neuropeptide Y Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology Endocrinology Cancer
M871 (Galanin-(2-13)-Glu-His-(Pro)3-(Ala-Leu)2-Ala-amide) is an orally active and selective galanin receptor type 2 (GalR2) antagonist. M871 exhibits K_i values of 13.1 nM, 420 nM and >10 μM for GalR2, GalR1 and GalR3 respectively. M871 relieves the mice allergic rhinitis by reducing IgE production, as well as the number of B cells in tissues. M871 can inhibit the nerve invasion of salivary adenoid cystic carcinoma (SACC) and alleviate myocardial ischemia-reperfusion injury. M871 can be used for research on GalR2-related diseases (such as epilepsy, pain) .

HY-174903

ITK-IN-6	Itk	Inflammation/Immunology
ITK-IN-6 is a highly potent and selective ITK inhibitor (K_d = 387 nM). ITK-IN-6 directly binds to the ITK kinase domain. ITK-IN-6 blocks the release of pro-inflammatory cytokines and the activation and differentiation of Th2 and Th17 cells. ITK-IN-6 improves asthma progression by reducing inflammatory cell infiltration, mucus and IgE production. ITK-IN-6 significantly inhibits airway inflammation and is used in asthma research .

HY-124146

BI1002494	Syk	Inflammation/Immunology
BI1002494 is an orally active, potent, and selective spleen tyrosine kinase (SYK) inhibitor. BI 1002494 exhibits an IC₅₀ of 115 nM in inhibiting high-affinity IgE receptor-mediated mast cell and basophil degranulation. BI1002494 can be utilized in immunology reesearch .

HY-13218

Acitazanolast WP-871	Histamine Receptor	Inflammation/Immunology
Acitazanolast is an orally active antiallergic agent, can inhibit histamine release. Acitazanolast can be used in study of type I anaphylaxis (immediate) caused by IgE antibodies .

HY-W062109S

Olopatadine-d6	Isotope-Labeled Compounds Histamine Receptor CXCR	Inflammation/Immunology
Olopatadine-d₆ is the deuterium labeled Olopatadine. Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific *IgE, while increasing the expression of ErbB3A/HER3A*. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .

HY-P991651

MEDI4212	Fc Receptor (FcR)	Inflammation/Immunology
MEDI4212 is a humanized IgG1λ monoclonal antibody inhibitor targeting *IgE. MEDI4212 potently inhibits* human IgE-mediated functional responses through its receptor FcεRI, such as calcium signaling, β-hexosaminidase release and phagocytosis. MEDI4212 prevents the binding of IgE to CD23 with an IC₅₀ of 8 nM. MEDI4212 can be used severe asthma research .

HY-125916

Pseurotin A	Endogenous Metabolite	Cancer
Pseurotin A is a secondary metabolite of Aspergillus and other fungi. Pseurotin A is a competitive inhibitor of chitin synthase and a neuritogenic agent. Pseurotin A inhibits *IgE* production (IC₅₀ = 3.6 μM). Pseurotin A inhibits the PCSK9-LDLr interaction. Pseurotin A shows dose-dependent reduction of PCSK9, along with increased LDLR levels in hormone-dependent breast cancer cell lines. Pseurotin A exhibits antitumor activity .

HY-176767

MrgprX2-IN-1	Mas-related G-protein-coupled Receptor (MRGPR)	Inflammation/Immunology
MrgprX2-IN-1 (Compound 2-10) is a selective Mas-related G-protein coupled receptor X2 (MRGPRX2) antagonist. MrgprX2-IN-1 blocks IgE-independent immune responses by inhibiting MRGPRX2-mediated mast cell degranulation and release of inflammatory mediators. MrgprX2-IN-1 is promising for research of pseudo-allergic reactions, chronic pruritus, and inflammatory diseases .

HY-176768

MrgprX2-IN-2	Mas-related G-protein-coupled Receptor (MRGPR)	Inflammation/Immunology
MrgprX2-IN-2 (Compound example 12) is a selective Mas-related G-protein coupled receptor X2 (MRGPRX2) antagonist. MrgprX2-IN-2 blocks IgE-independent immune responses by inhibiting MRGPRX2-mediated mast cell degranulation and release of inflammatory mediators. MrgprX2-IN-2 is promising for research of pseudo-allergic reactions, chronic pruritus, and inflammatory diseases .

HY-N15708

Dichotomine C (R)-(-)-Dichotomine C	Glycosidase TNF Receptor Interleukin Related	Inflammation/Immunology
Dichotomine C ((R)-(-)-Dichotomine C) is a β-carboline-type alkaloid with antiallergic effects. Dichotomine C inhibits the release of β-hexosaminidase in RBL-2H3 cells with an IC₅₀ of 62 μM. Dichotomine C inhibits the releases of antigen-IgE-mediated TNF-α and IL-4 in RBL-2H3 cells with IC₅₀s of 19 μM and 15 μM, respectively. Dichotomine C can be used for the study of type I allergic reactions .

HY-B0426AS

Olopatadine-d3 hydrochloride	Isotope-Labeled Compounds Histamine Receptor CXCR	Inflammation/Immunology Endocrinology
Olopatadine-d₃ hydrochloride (ALO4943A-d₃) is the deuterium labeled Olopatadine hydrochloride. Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific *IgE, while increasing the expression of ErbB3A/HER3A*. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .

HY-B0426AR

Olopatadine hydrochloride (Standard) ALO4943A (Standard); KW4679 (Standard)	Reference Standards Histamine Receptor CXCR	Inflammation/Immunology Endocrinology
Olopatadine (hydrochloride) (Standard) is the analytical standard of Olopatadine (hydrochloride). This product is intended for research and analytical applications. Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific *IgE, while increasing the expression of ErbB3A/HER3A*. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .

HY-165484

AVP-13358	Interleukin Related	Inflammation/Immunology
AVP-13358 is an orally active *IgE* inhibitor that effectively suppresses immunoglobulin E (IgE)-mediated immune responses, with IC₅₀ values of 8 and 3 nM for *IgE* inhibition in vivo and in vitro in BALB/c mice, respectively. AVP-13358 acts directly on T cells, inhibiting the production and release of IL-4, IL-5, and IL-13. It also targets other markers critical for the development of allergic responses, including the B cell *IgE* receptor (CD23) in human monocytes and the CD23 and IL-4 receptors in mouse B cells. AVP-13358 can be used in research related to anti-allergic responses .

HY-159926

Tixanox sodium RS-7540	Histamine Receptor	Inflammation/Immunology
Tixanox sodium (RS-7540), an anti-allergic compound, is a potent inhibitor of mediator release in the IgE-mediated passive cutaneous anaphylaxis (PCA) reaction .

HY-N14193

Estatin B	Cathepsin	Inflammation/Immunology
Estatin B is a thiol protease inhibitor found by the Thermophilic Bacterium M4323, which is specific to thiol proteases such as papain, fig protease, and bromelain. Estatin B inhibits the production of IgE antibodies but not IgG in mice .

HY-137787R

Cyanosafracin B (Standard)	Drug Intermediate Reference Standards	Others
Nylidrin (hydrochloride) (Standard) is the analytical standard of Nylidrin (hydrochloride). This product is intended for research and analytical applications. Nylidrin hydrochloride is an inhibitor of IgE-mediated histamine release in passive sensitized rat peritoneal mast cells, and it has anti-allergic effects.

$Cyanosafracin B (Standard)$

HY-114538

Asobamast	TNF Receptor	Cardiovascular Disease Inflammation/Immunology
Asobamast is a potent, orally active antiallergic agent that inhibits ige mediated passive pulmonary allergic responses in rats (ED₅₀=4.7 mg/kg) and inhibits antigen-induced mediator release from sensitized guinea pig lung fragments .

HY-W754020

Elbanizine	Histamine Receptor	Others
Elbanizine inhibits histamine, bradykinin, histamin-release from rat mast cells (IC₅₀ of 0.26 μM) and the IgE-mediated passive cutaneous anaphylaxis (PCA) reaction. Elbanizine exhibits antiallergic and antiasthmatic in guinea pig model .

HY-N12261

Benastatin B	Glutathione S-transferase Bacterial	Infection Inflammation/Immunology Cancer
Benastatin B is an inhibitor for glutathione S-transferase, that inhibits human pi class GST with an IC₅₀ of 1.10 μg/mL. Benastatin B exhibits board-spectrum antibacterial efficacy, inhibits MRSA with MIC 3.1 μg/mL. Benastatin B exhibits anti-inflammatory efficacy through inhibition of IgE mediated β-hexosaminidase release with an IC₅₀ of 79 μg/mL .

HY-139247

pNPS-DHA	Drug Derivative	Inflammation/Immunology
pNPS-DHA (Compound 19) is an orally active DHA-ethanolamide (DHEA) derivative that has antiallergic activity. pNPS-DHA inhibits IgE-dependent passive cutaneous anaphylaxis (PCA) reaction in mice. pNPS-DHA has anti-degranulating activity in RBL-2H3 mast cells with an IC₅₀ of 15 μM .

HY-167715

Traxanox	Histamine Receptor Phosphodiesterase (PDE)	Inflammation/Immunology
Traxanox is an orally available diuretic that enhances phagocytosis of yeast granules by mouse peritoneal macrophages and rat peritoneal polymorphonuclear leukocytes in vitro. Traxanox inhibits IgE-mediated histamine release and cyclic AMP phosphodiesterase activity.Traxanox exhibits anti-inflammatory activity, as it inhibits the anaphylactoid reaction and reduces pleural fluid accumulation in experimental models of inflammation. Traxanox also demonstrates a synergistic effect when combined with hydrocortisone or indomethacin in suppressing adjuvant arthritis in rats.

HY-19108

CI-959	Reactive Oxygen Species (ROS) Histamine Receptor	Inflammation/Immunology Endocrinology
CI-959 is an inhibitor of inflammatory cell activation. CI-959 exhibits anti-inflammatory and anti-allergic activities. CI-959 can inhibit the production of reactive oxygen species by neutrophils, as well as neutrophil adhesion, respiratory burst, and histamine release from mast cells. CI-959 can also inhibit the release of inflammatory mediators such as histamine, leukotrienes, and thromboxane from guinea-pig and human lung tissues, and effectively suppress anti-IgE-induced contractions of human bronchial smooth muscle. CI-959 can be used in the research of inflammatory and allergic diseases, such as asthma .

HY-N0631R

Cornuside (Standard)	Reference Standards Prostaglandin Receptor ERK p38 MAPK Acyltransferase TNF Receptor COX Cholinesterase (ChE) Interleukin Related JNK NO Synthase NF-κB	Neurological Disease Inflammation/Immunology
Cornuside (Standard) is the analytical standard of Cornuside (HY-N0631). This product is intended for research and analytical applications. Cornuside is an iridoid glycoside with anti-allergic, anti-inflammatory, and neuroprotective activities. Cornuside exerts anti-allergic activity by downregulating the p38 MAPK, JNK, and NF-κB signaling pathways, and inhibits IgE-mediated histamine release from mast cells. Cornuside improves cognitive impairment in mice by inhibiting BACE1 activity (IC₅₀ = 55.84 μg/mL) and enhancing ChAT activity. Cornuside inhibits LPS (HY-D1056)-induced inflammatory mediators, including iNOS, COX-2, PGE2, TNF-α, IL-6, and IL-1β, by suppressing NF-κB activation.

HY-B0426AS2

Olopatadine-d6 hydrochloride ALO4943A-d6 hydrochloride; KW4679-d6 hydrochloride	Isotope-Labeled Compounds Histamine Receptor CXCR	Inflammation/Immunology
Olopatadine-d₆ (ALO4943A-d₆; KW4679-d₆) hydrochloride is deuterium-labeled Olopatadine (hydrochloride) (HY-B0426A). Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific *IgE, while increasing the expression of ErbB3A/HER3A*. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .

HY-N11725

Phlorofucofuroeckol A	Fc Receptor (FcR)	Inflammation/Immunology
Phlorofucofuroeckol A is a FcεRI inhibitor with low cytotoxicity toward basophilic leukemia cells. Phlorofucofuroeckol A suppresses binding activity between IgE and FcεRI receptor. Phlorofucofuroeckol A inhibits histamine release from basophilic leukemia cells stimulated by IgE/anti-IgE or calcium ionophore A23187 (HY-N6687). Phlorofucofuroeckol A inhibits β-hexosaminidase release from basophilic leukemia cells stimulated by IgE/DNP-BSA. Phlorofucofuroeckol A can be used for the research of allergy disease .

HY-105594

Nivimedone BRL 10833 free base	Histamine Receptor	Inflammation/Immunology
Nivimedone (BRL 10833 free base) is an orally active antiallergic agent. Nivimedone inhibits IgE-mediated passive cutaneous anaphylaxis in rats. Nivimedone suppresses antigen-induced histamine release from lung tissues passively sensitized with atopic serum. Nivimedone can be used in research related to bronchial asthma .

HY-N17651

Tricetinidin chloride	Reactive Oxygen Species (ROS) Fc Receptor (FcR) Heme Oxygenase (HO)	Inflammation/Immunology
Tricetinidin chloride is an antioxidant. Tricetinidin chloride protects rat renal cells against oxidative stress and DNA damage by reducing ROS production, increasing GSH levels, restoring mitochondrial membrane potential, and upregulating HO-1 expression. Tricetinidin chloride also inhibits the expression of IgE receptors on human mast cells. Tricetinidin chloride can be used in the research of inflammatory and allergic diseases .

HY-107062

AA 344	Histamine Receptor	Inflammation/Immunology
AA 344 is an orally active antiallergic agent. AA 344 inhibits the IgE, IgGa, Concanavalin A (HY-P2149), Dextran -mediated release of histamine. AA 344 shows inhibitory effects on the homologous passive cutaneous anaphylaxis and the passive systemic anaphylaxis in guinea pigs. AA 344 selectively suppresses the type I allergic reaction .

HY-165395

AY 25674	Phosphodiesterase (PDE)	Inflammation/Immunology
AY 25674 is an orally active antiallergic agent and a PDE inhibitor. AY 25674 inhibits the release of allergic histamine from mast cells. AY 25674 suppresses passive anaphylaxis induced by reaginic (IgE) antibodies. AY 25674 does not inhibit the increased vascular permeability caused by non-reaginic antibodies, serotonin or histamine. AY 25674 reaches its peak activity shortly after administration; rapid tolerance occurs at high doses. AY 25674 can be used in research related to passive anaphylaxis .

HY-180165

Antiallergic agent-5	Calcium Channel Interleukin Related	Cardiovascular Disease Inflammation/Immunology
Antiallergic agent-5 (Compound 4f) is an antiallergic agent. Antiallergic agent-5 suppresses Ca ²⁺ influx. Antiallergic agent-5 suppresses IgE/Ag-induced release of both IL-6 and TNF-α. Antiallergic agent-5 inhibits mast cell degranulation. Antiallergic agent-5 attenuates passive cutaneous anaphylaxis in mice and reduces vascular leakage .

HY-105360

GI-129471	MMP	Inflammation/Immunology Cancer
GI-129471 is a MMP inhibitor. GI-129471 exhibits inhibitory activity against cancer cell invasion. GI-129471 can completely block the enhanced production of IgE and IgG1 by mouse B cells induced by rat mast cell protease-I (RMCP-I). GI-129471 can be used for the study of cancer and mast cell chymase-regulated immunological processes .

HY-P992447

QX008N	Interleukin Related	Inflammation/Immunology
QX008N is a humanized IgG1 monoclonal antibody and also a TSLP inhibitor with a K_D value of 0.0175 nM. QX008N blocks TSLP-induced signaling pathways by inhibiting the interaction of TSLP-TSLPR-IL-7Rα. QX008N reduces eosinophil and IgE levels, improves pulmonary function, blocks TSLP-induced inflammation, and enhances the inhibitory effect on inflammatory mediators when administered in combination with anti-IL-4R antibodies. QX008N is applicable to relevant research on asthma .

HY-183548

XW-17	PARP	Inflammation/Immunology
XW-17 is a PARP14 inhibitor with an IC₅₀ of 3.03 nM and selectivity over other PARP family members.XW-17 suppresses PARP14-mediated mono-ADP-ribosylation, engages and stabilizes endogenous PARP14 protein.XW-17 attenuates skin lesions and decreases expression of IL-4, IL-13, IgE, and IL-17A in an atopic dermatitis-like mouse model.XW-17 can be used for the research of atopic dermatitis .

HY-181576

ROCK2-IN-14	ROCK	Inflammation/Immunology
ROCK2-IN-14 is an orally active, selective ROCK2 inhibitor (IC₅₀=4.8 nM) with 212-fold selectivity over ROCK1 (IC₅₀=1.01 μM). By inhibiting the ROCK2/S100A9 signaling pathway, ROCK2-IN-14 downregulates S100A9 expression, inhibits NM2 phosphorylation and restores cytoskeletal abnormalities. Furthermore, ROCK2-IN-14 reduces inflammatory cytokine levels, alleviates skin inflammation and exerts anti-inflammatory activity. ROCK2-IN-14 also significantly inhibits ear thickening in a mouse model of atopic dermatitis (AD), and decreases the levels of IgE, TNF-α, IL-6 and TSLP. ROCK2-IN-14 can be used for research on atopic dermatitis .

HY-N17617

S-Petasin	Phosphodiesterase (PDE) Apoptosis NO Synthase Caspase PPAR Bcl-2 Family PARP	Metabolic Disease Inflammation/Immunology Cancer
S-Petasin is a phosphodiesterase (PDE) inhibitor with IC₅₀ values of 25.5 μM and 17.5 μM for PDE3 and PDE4, respectively. S-Petasin inhibits cholesterol side-chain cleavage enzyme, 11β-hydroxylase, PPAR-γ, and iNOS induction at RNA and protein levels. S-Petasin induces apoptosis, activates caspases, cleaves PARP, modulates mitochondrial membrane permeability, and regulates BCL2/BAX, p53, Bcl-XL, MMP-2, MMP-9, p21, CDK4, and cyclin D1 expression. S-Petasin reduces inflammatory cell accumulation, cytokine and IgE levels, and enhances serum IgG2a levels. S-Petasin relaxes isolated sensitized guinea pig trachealis and exhibits gastrointestinal anti-spasmodic activity. S-Petasin reduces tonsillitis severity and asthmatic attack frequency. S-Petasin can be used for the research of prostate cancer, obesity, melanoma, allergic asthma, asthma, and peritonitis .

製品番号	製品名	Target	研究分野

HY-P1130

M871 Galanin-(2-13)-Glu-His-(Pro)3-(Ala-Leu)2-Ala-amide	Neuropeptide Y Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology Endocrinology Cancer
M871 (Galanin-(2-13)-Glu-His-(Pro)3-(Ala-Leu)2-Ala-amide) is an orally active and selective galanin receptor type 2 (GalR2) antagonist. M871 exhibits K_i values of 13.1 nM, 420 nM and >10 μM for GalR2, GalR1 and GalR3 respectively. M871 relieves the mice allergic rhinitis by reducing IgE production, as well as the number of B cells in tissues. M871 can inhibit the nerve invasion of salivary adenoid cystic carcinoma (SACC) and alleviate myocardial ischemia-reperfusion injury. M871 can be used for research on GalR2-related diseases (such as epilepsy, pain) .

製品番号	製品名	Target	研究分野	Image

HY-P990774

Verekitug ASP-7266; TRAB-1; UPB-101	Interleukin Related	Inflammation/Immunology
Verekitug (ASP-7266; TRAB-1; UPB-101) is a human monoclonal antibody targeting the thymic stromal lymphopoietin receptor (TSLPR), with a mean half-life of approximately 20 days. At doses of Verekitug ≥100 mg, complete and sustained TSLPR-specific occupancy is achieved, and the antibody does not bind to IL-7Rα. By inhibiting TSLP-driven inflammatory responses, Verekitug blocks TSLP-induced cell proliferation and TARC expression, while reducing fractional exhaled NO levels, blood eosinophil counts, and levels of IL-5 and *IgE*. Verekitug significantly improves scores for nasal polyps, nasal congestion and olfactory dysfunction, with favorable safety and good tolerability; potential adverse reactions include headache, upper respiratory tract infection, sinusitis and nasopharyngitis. Verekitug is used in relevant studies on asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease .

HY-P99300

Ligelizumab 1 Publications Verification QGE 031; Anti-IGHE Recombinant Antibody	Fc Receptor (FcR)	Inflammation/Immunology
Ligelizumab (QGE 031) is a humanized high-affinity anti-immunoglobulin *IgE* monoclonal antibody. Ligelizumab selectively inhibits the binding of IgE to the high-affinity receptor FcεRI, while the inhibitory effect on the low-affinity receptor CD23 is weak. Ligelizumab can inhibit the activation of effector cells such as mast cells and Basophil, while reducing the production of IgE by B cells, and restoring the IFN-α production and regulatory T cell (Treg) induction function of plasmacytoid dendritic cells (pDC). Ligelizumab can be used in the study of allergic diseases (such as chronic spontaneous urticaria, allergic asthma) .

HY-P99371

Lirentelimab AK002; Antolimab	Apoptosis	Inflammation/Immunology
Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis .

HY-P991636

AK006	Transmembrane Glycoprotein	Inflammation/Immunology
AK006 is a humanized IgG1 monoclonal antibody agonist targeting Sialic acid-binding immunoglobulin-like lectin6 (Siglec-6). AK006 potently inhibits IgE-mediated human mast cell activation. AK006 can be used for inflammatory diseases like chronic urticaria (CU) and asthma research .

HY-P991592

UB-221	阻害性抗体	Inflammation/Immunology
UB-221 is a humanized IgG1 monoclonal antibody inhibitor targeting *IgE. UB-221 significantly decreases IgE* synthesis by stabilization of membrane-bound CD23 on B lymphocytes and inhibits FcԑRI-mediated basophil activation and degranulation. UB-221 reduces IgE level in cynomolgus macaques and human IgE (ε, κ)-transgenic (hIGHE-knockin) mice. UB-221 can be used for asthma and chronic spontaneous urticaria (CSU) research .

HY-P991651

MEDI4212	Fc Receptor (FcR)	Inflammation/Immunology
MEDI4212 is a humanized IgG1λ monoclonal antibody inhibitor targeting *IgE. MEDI4212 potently inhibits* human IgE-mediated functional responses through its receptor FcεRI, such as calcium signaling, β-hexosaminidase release and phagocytosis. MEDI4212 prevents the binding of IgE to CD23 with an IC₅₀ of 8 nM. MEDI4212 can be used severe asthma research .

HY-P992447

QX008N	Interleukin Related	Inflammation/Immunology
QX008N is a humanized IgG1 monoclonal antibody and also a TSLP inhibitor with a K_D value of 0.0175 nM. QX008N blocks TSLP-induced signaling pathways by inhibiting the interaction of TSLP-TSLPR-IL-7Rα. QX008N reduces eosinophil and IgE levels, improves pulmonary function, blocks TSLP-induced inflammation, and enhances the inhibitory effect on inflammatory mediators when administered in combination with anti-IL-4R antibodies. QX008N is applicable to relevant research on asthma .

製品番号	製品名	Category	Target	構造式

HY-N0631

Cornuside 5+ Cited Publications	Structural Classification Iridoids Cornaceae Classification of Application Fields Cornus officinalis Sieb. et Zucc. Terpenoids Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields Source Classification	p38 MAPK NF-κB JNK Cholinesterase (ChE) Acyltransferase NO Synthase Interleukin Related TNF Receptor Prostaglandin Receptor ERK COX
Cornuside is an iridoid glycoside with anti-allergic, anti-inflammatory, and neuroprotective activities. Cornuside exerts anti-allergic activity by downregulating the p38 MAPK, JNK, and NF-κB signaling pathways, and inhibits IgE-mediated histamine release from mast cells. Cornuside improves cognitive impairment in mice by inhibiting BACE1 activity (IC₅₀ = 55.84 μg/mL) and enhancing ChAT activity. Cornuside inhibits LPS (HY-D1056)-induced inflammatory mediators, including iNOS, COX-2, PGE2, TNF-α, IL-6, and IL-1β, by suppressing NF-κB activation .

HY-114495

Caerulomycin A 3 Publications Verification Cerulomycin; Caerulomycin	Structural Classification Microorganisms Anti-inflammation/Immunoregulatory Classification of Application Fields Antibiotics Antibacterial Disease Research Anticancer Inflammation/Immunology Disease Research Fields Other Antibiotics Source Classification	Fungal Antibiotic
Caerulomycin A is an orally active immunomodulator and antimicrobial agent. Caerulomycin A targets Smad3, STAT1 and GATA-3. Caerulomycin A downregulates GATA-3 expression, inhibits Th2 cell differentiation and Th2 cytokine production, reduces IgE levels, and alleviates pulmonary inflammatory responses and eosinophil infiltration. Caerulomycin A ameliorates collagen-induced arthritis symptoms, reduces joint inflammation and synovitis, and decreases the levels of proinflammatory cytokines in joints. Caerulomycin A inhibits the growth of some filamentous fungi, yeasts and specific bacteria. Caerulomycin A can be used in research related to arthritis and asthma .

HY-B0426A

Olopatadine hydrochloride ALO4943A; KW4679	Structural Classification Alkaloids Classification of Application Fields Ketones, Aldehydes, Acids Other Alkaloids Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Histamine Receptor CXCR
Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific *IgE, while increasing the expression of ErbB3A/HER3A*. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .

HY-W062109

Olopatadine	Structural Classification Alkaloids Classification of Application Fields Other Alkaloids Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Histamine Receptor CXCR
Olopatadine (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific *IgE, while increasing the expression of ErbB3A/HER3A*. Olopatadine can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .

HY-125916

Pseurotin A	Alkaloids Microorganisms Pyrrole Alkaloids Classification of Application Fields Disease Research Fields Source Classification Cancer	Endogenous Metabolite
Pseurotin A is a secondary metabolite of Aspergillus and other fungi. Pseurotin A is a competitive inhibitor of chitin synthase and a neuritogenic agent. Pseurotin A inhibits *IgE* production (IC₅₀ = 3.6 μM). Pseurotin A inhibits the PCSK9-LDLr interaction. Pseurotin A shows dose-dependent reduction of PCSK9, along with increased LDLR levels in hormone-dependent breast cancer cell lines. Pseurotin A exhibits antitumor activity .

HY-N15708

Dichotomine C (R)-(-)-Dichotomine C	Alkaloids Stellaria dichotoma L. Plants Caryophyllaceae Indole Alkaloids Source Classification	Glycosidase TNF Receptor Interleukin Related
Dichotomine C ((R)-(-)-Dichotomine C) is a β-carboline-type alkaloid with antiallergic effects. Dichotomine C inhibits the release of β-hexosaminidase in RBL-2H3 cells with an IC₅₀ of 62 μM. Dichotomine C inhibits the releases of antigen-IgE-mediated TNF-α and IL-4 in RBL-2H3 cells with IC₅₀s of 19 μM and 15 μM, respectively. Dichotomine C can be used for the study of type I allergic reactions .

HY-B0426AR

Olopatadine hydrochloride (Standard) ALO4943A (Standard); KW4679 (Standard)	Structural Classification Alkaloids Ketones, Aldehydes, Acids Other Alkaloids Endogenous metabolite Source Classification	Reference Standards Histamine Receptor CXCR
Olopatadine (hydrochloride) (Standard) is the analytical standard of Olopatadine (hydrochloride). This product is intended for research and analytical applications. Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific *IgE, while increasing the expression of ErbB3A/HER3A*. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .

HY-N14193

Estatin B	Microorganisms Antibiotics Other Antibiotics Source Classification	Cathepsin
Estatin B is a thiol protease inhibitor found by the Thermophilic Bacterium M4323, which is specific to thiol proteases such as papain, fig protease, and bromelain. Estatin B inhibits the production of IgE antibodies but not IgG in mice .

HY-137787R

Cyanosafracin B (Standard)	Microorganisms Marine natural products Source Classification	Drug Intermediate Reference Standards
Nylidrin (hydrochloride) (Standard) is the analytical standard of Nylidrin (hydrochloride). This product is intended for research and analytical applications. Nylidrin hydrochloride is an inhibitor of IgE-mediated histamine release in passive sensitized rat peritoneal mast cells, and it has anti-allergic effects.

$Cyanosafracin B (Standard)$

HY-N12261

Benastatin B	Microorganisms Phenols Polyphenols Source Classification	Glutathione S-transferase Bacterial
Benastatin B is an inhibitor for glutathione S-transferase, that inhibits human pi class GST with an IC₅₀ of 1.10 μg/mL. Benastatin B exhibits board-spectrum antibacterial efficacy, inhibits MRSA with MIC 3.1 μg/mL. Benastatin B exhibits anti-inflammatory efficacy through inhibition of IgE mediated β-hexosaminidase release with an IC₅₀ of 79 μg/mL .

HY-N0631R

Cornuside (Standard)	Structural Classification Iridoids Cornaceae Cornus officinalis Sieb. et Zucc. Terpenoids Phenols Polyphenols Plants Source Classification	Reference Standards Prostaglandin Receptor ERK p38 MAPK Acyltransferase TNF Receptor COX Cholinesterase (ChE) Interleukin Related JNK NO Synthase NF-κB
Cornuside (Standard) is the analytical standard of Cornuside (HY-N0631). This product is intended for research and analytical applications. Cornuside is an iridoid glycoside with anti-allergic, anti-inflammatory, and neuroprotective activities. Cornuside exerts anti-allergic activity by downregulating the p38 MAPK, JNK, and NF-κB signaling pathways, and inhibits IgE-mediated histamine release from mast cells. Cornuside improves cognitive impairment in mice by inhibiting BACE1 activity (IC₅₀ = 55.84 μg/mL) and enhancing ChAT activity. Cornuside inhibits LPS (HY-D1056)-induced inflammatory mediators, including iNOS, COX-2, PGE2, TNF-α, IL-6, and IL-1β, by suppressing NF-κB activation.

HY-N11725

Phlorofucofuroeckol A	Structural Classification Microorganisms Phenols Polyphenols Source Classification	Fc Receptor (FcR)
Phlorofucofuroeckol A is a FcεRI inhibitor with low cytotoxicity toward basophilic leukemia cells. Phlorofucofuroeckol A suppresses binding activity between IgE and FcεRI receptor. Phlorofucofuroeckol A inhibits histamine release from basophilic leukemia cells stimulated by IgE/anti-IgE or calcium ionophore A23187 (HY-N6687). Phlorofucofuroeckol A inhibits β-hexosaminidase release from basophilic leukemia cells stimulated by IgE/DNP-BSA. Phlorofucofuroeckol A can be used for the research of allergy disease .

HY-N17651

Tricetinidin chloride	Gesneriaceae Structural Classification Rhabdothamnus solandriA.Cunn. Phenols Plants Source Classification	Reactive Oxygen Species (ROS) Fc Receptor (FcR) Heme Oxygenase (HO)
Tricetinidin chloride is an antioxidant. Tricetinidin chloride protects rat renal cells against oxidative stress and DNA damage by reducing ROS production, increasing GSH levels, restoring mitochondrial membrane potential, and upregulating HO-1 expression. Tricetinidin chloride also inhibits the expression of IgE receptors on human mast cells. Tricetinidin chloride can be used in the research of inflammatory and allergic diseases .

HY-N17617

S-Petasin	Structural Classification 天然物 Plants Petasites hybridus (L.) G.Gaertn., B.Mey. & Schreb. Compositae Source Classification	Phosphodiesterase (PDE) Apoptosis NO Synthase Caspase PPAR Bcl-2 Family PARP
S-Petasin is a phosphodiesterase (PDE) inhibitor with IC₅₀ values of 25.5 μM and 17.5 μM for PDE3 and PDE4, respectively. S-Petasin inhibits cholesterol side-chain cleavage enzyme, 11β-hydroxylase, PPAR-γ, and iNOS induction at RNA and protein levels. S-Petasin induces apoptosis, activates caspases, cleaves PARP, modulates mitochondrial membrane permeability, and regulates BCL2/BAX, p53, Bcl-XL, MMP-2, MMP-9, p21, CDK4, and cyclin D1 expression. S-Petasin reduces inflammatory cell accumulation, cytokine and IgE levels, and enhances serum IgG2a levels. S-Petasin relaxes isolated sensitized guinea pig trachealis and exhibits gastrointestinal anti-spasmodic activity. S-Petasin reduces tonsillitis severity and asthmatic attack frequency. S-Petasin can be used for the research of prostate cancer, obesity, melanoma, allergic asthma, asthma, and peritonitis .

製品番号	製品名	構造式

HY-W062109S

Olopatadine-d6

Olopatadine-d₆ is the deuterium labeled Olopatadine. Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .

HY-B0426AS

Olopatadine-d3 hydrochloride

Olopatadine-d₃ hydrochloride (ALO4943A-d₃) is the deuterium labeled Olopatadine hydrochloride. Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .

HY-B0426AS2

Olopatadine-d6 hydrochloride

Olopatadine-d₆ (ALO4943A-d₆; KW4679-d₆) hydrochloride is deuterium-labeled Olopatadine (hydrochloride) (HY-B0426A). Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 ⁺ and CD8 ⁺ T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .

オンラインお問い合わせ

入力情報は安全に管理されます. ※ 必須入力項目.

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
タイトル			国或いは地域 *
お名前 *			組纖名 *
デパートメント *
メールアドレス *			製品名 *
製品番号			カスタマ需要量 *
電話番号 *
必ず会社名を記載ください。個人への返信は行いません。
備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店: